Peter van der Ark

Peter van der Ark

Auto-generated profile, based on publicly available information

Peter van der Ark

Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
SBSander Brooks
Sander Brooks
GJGabriël E Jacobs
Gabriël E Jacobs
PBPeter de Boer
Peter de Boer
JKJustine M Kent
Justine M Kent
LNLuc Van Nueten
Luc Van Nueten
WDWayne Drevets
Wayne Drevets
Insomnia is common in patients with major depressive disorder. Although antidepressants improve mood, insomnia often persists as a result of physiological hyperarousal. The orexin-2 receptor is increasingly being recognized as a new target for the treatment of persistent insomnia in major depressive disorder . This exploratory study investigated the effects of seltorexant on objective sleep parameters and subjective depressive symptoms in antidepressant treated major depressive disorder patients with persistent insomnia. Twenty male and female patients received a single dose of 10, 20, 40 mg seltorexant and placebo with a washout period of seven days in a double-blind four-way crossover study. Effects on latency to persistent sleep, total sleep time and sleep efficiency were assessed with polysomnography. Subjective changes in mood were explored by the Quick Inventory of Depressive Symptomatology Self-Report. Safety was recorded and suicidal ideation and behavior were assessed with the Columbia Suicide Severity Rating Scale. Latency to persistent sleep was significantly shorter for all doses of seltorexant compared to placebo. Placebo least square mean was 61.05 min with least square mean ratios treatment/placebo (80% confidence interval) of 0.32 (0.24–0.44), 0.15 (0.11–0.2) and 0.17 (0.12–0.23) 19.69, 9.2, 10.15 for 10, 20 and 40 mg seltorexant respectively, (all p<0.001). Total sleep time was significantly longer for all doses of seltorexant compared to placebo. Sleep efficiency was significantly improved. The Quick Inventory of Depressive Symptomatology Self-Report demonstrated a trend to mood-improvement for the 40 mg group. Seltorexant showed a statistically significant, dose-dependent decrease in latency to persistent sleep, and increase in total sleep time and sleep efficiency combined with a tendency toward subjectively improved mood.

31 May 2018 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PBPeter De Boer
Peter De Boer
WDWayne C Drevets
Wayne C Drevets
HRHany Rofael
Hany Rofael
PAPeter van der Ark
Peter van der Ark
JKJustine M Kent
Justine M Kent
RLRemy Luthringer
Remy Luthringer
Seltorexant is a potent and selective antagonist of the orexin-2 receptor that is being developed for the treatment of insomnia and major depressive disorder. The primary objective was to investigate the effect of seltorexant on sleep efficiency after single and multiple dose administration in subjects with insomnia disorder without psychiatric comorbidity. Secondary objectives included evaluation of total sleep time, latency to persistent sleep, and wake after sleep onset. Subjects received 40 mg of seltorexant for five days during Period 1 and placebo during Period 2 or vice versa in this randomized, two-way crossover study. Objective sleep parameters were evaluated by polysomnography over 8 h on Day 1/2 (single dose) and on Day 5/6 (multiple doses). Subjective sleep parameters were assessed by questionnaires. Twenty-seven subjects completed the study. The mean changes in sleep efficiency (% (SD)) of seltorexant from placebo at Day 1/2 were 5.8 (9.2), and 7.9 (9.8) at Day 5/6 (p < 0.001 at both time points); in total sleep time (min (SD)) 27.7 (44.3) and 37.9 (47.1), respectively; in latency to persistent sleep (min (SD)) −18.8 (21.3) and −29.9 (27.7), respectively; and in wake after sleep onset (min (SD)) −11.1 (36.4) and −11.3 (46.5). The most common adverse events were headache and somnolence. Sleep efficiency was increased with seltorexant treatment compared with placebo. Treatment with seltorexant resulted in a prolonged total sleep time, shorter latency to persistent sleep and wake after sleep onset. There were no unexpected safety findings.

20 April 2021 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
HLHeikki Lukkarinen
Heikki Lukkarinen
ITIna Tesseur
Ina Tesseur
DPDarrel Pemberton
Darrel Pemberton
PAPeter Van Der Ark
Peter Van Der Ark
MTMaarten Timmers
Maarten Timmers
VLVille Leinonen
Ville Leinonen
Background: Longitudinal changes in cerebrospinal fluid (CSF) biomarkers are seldom studied. Furthermore, data on biomarker gradient between lumbar (L-) and ventricular (V-) compartments seems to be discordant. Objective: To examine alteration of CSF biomarkers reflecting Alzheimer’s disease (AD)-related amyloid-β (Aβ) aggregation, tau pathology, neurodegeneration, and early synaptic degeneration by CSF shunt surgery in idiopathic normal pressure hydrocephalus (iNPH) in relation to AD-related changes in brain biopsy. In addition, biomarker levels in L- and V-CSF were compared. Methods: L-CSF was collected prior to shunt placement and, together with V-CSF, 3–73 months after surgery. Thereafter, additional CSF sampling took place at 3, 6, and 18 months after the baseline sample from 26 iNPH patients with confirmed Aβ plaques in frontal cortical brain biopsy and 13 iNPH patients without Aβ pathology. CSF Amyloid-β42 (Aβ42), total tau (T-tau), phosphorylated tau (P-tau181), neurofilament light (NFL), and neurogranin (NRGN) were analyzed with customized ELISAs. Results: All biomarkers but Aβ42 increased notably by 140–810% in L-CSF after CSF diversion and then stabilized. Aβ42 instead showed divergent longitudinal decrease between Aβ-positive and -negative patients in L-CSF, and thereafter increase in Aβ-negative iNPH patients in both L- and V-CSF. All five biomarkers correlated highly between V-CSF and L-CSF (Aβ42 R = 0.87, T-tau R = 0.83, P-tau R = 0.92, NFL R = 0.94, NRGN R = 0.9; all p < 0.0001) but were systematically lower in V-CSF (Aβ42 14 %, T-tau 22%, P-tau 20%, NFL 32%, NRGN 19%). With APOE genotype-grouping, only Aβ42 showed higher concentration in non-carriers of allele ɛ4. Conclusion: Longitudinal follow up shows that after an initial post-surgery increase, T-tau, P-tau, and NRGN are stable in iNPH patients regardless of brain biopsy Aβ pathology, while NFL normalized toward its pre-shunt levels. Aβ42 as biomarker seems to be the least affected by the surgical procedure or shunt and may be the best predictor of AD risk in iNPH patients. All biomarker concentrations were lower in V- than L-CSF yet showing strong correlations.

5 September 2018 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PAPeter D van der Ark
Peter D van der Ark
GGGeorg Golor
Georg Golor
LNLuc van Nueten
Luc van Nueten
PNPartha Nandy
Partha Nandy
PBPeter de Boer
Peter de Boer
Background: Pharmacokinetics, pharmacodynamics and general safety and tolerability of JNJ-42847922, a selective orexin-2 receptor antagonist, were assessed in healthy subjects. Methods: Five consecutive cohorts of healthy subjects were enrolled and received doses of 5–60 mg orally once daily over 10 days of JNJ-42847922 ( n=6) or placebo ( n=2). Concentrations of drug in plasma and urine were measured over 24 h after dosing on Days 1, 5 and 10. Observed- and self-reported somnolence was used to evaluate the principal pharmacodynamic effect of JNJ-42847922. A test battery to assess vigilance state, sedation and alertness was assessed at 4, 6 and 8 h after dosing. Safety assessments included recording of adverse events, vital signs, electrocardiograms, clinical laboratory assessments and suicidality per Columbia Suicide Severity Rating Scale. Results: JNJ-42847922 was rapidly absorbed after the morning dose administration. The median tmax ranged from 0.5–1.5 h and mean t1/2 values from 2–3 h. At JNJ-42847922 dose levels ⩾20 mg, mean Cmax and mean area under the curve, values increased less than dose proportionally. At doses ⩾20 mg, JNJ-42847922 consistently induced somnolence on all study days. At four hours post-dose administration, dose levels >5 mg JNJ-42847922 were identified as sedating by the Addiction Research Center Inventory-49. Except for a mild decrease in attention (Bond and Lader Visual Analogue Scale Factor 1) at dose levels >10 mg at four hours post-dose, no clinically relevant changes in other central measures have been observed. JNJ-42847922 was well tolerated.

31 May 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
VLVille Leinonen
Ville Leinonen
TRTuomas Rauramaa
Tuomas Rauramaa
JJJarkko Johansson
Jarkko Johansson
ABAstrid Bottelbergs
Astrid Bottelbergs
ITIna Tesseur
Ina Tesseur
JRJuha Rinne
Juha Rinne
Background: Detection of pathological tau aggregates could facilitate clinical diagnosis of Alzheimer’s disease (AD) and monitor drug effects in clinical trials. S-[ 18 F]THK-5117 could be a potential tracer to detect pathological tau deposits in brain. However, no previous study have correlated S-[ 18 F]THK-5117 uptake in PET with brain biopsy verified tau pathology in vivo. Objective: Here we aim to evaluate the association between cerebrospinal fluid (CSF) AD biomarkers, S-[ 18 F]THK-5117, and [ 11 C]PIB PET against tau and amyloid lesions in brain biopsy. Methods: Fourteen patients with idiopathic normal pressure hydrocephalus (iNPH) with previous shunt surgery including right frontal cortical brain biopsy and CSF Aβ 1 - 42 , total tau, and P-tau 181 measures, underwent brain MRI, [ 11 C]PIB PET, and S-[ 18 F]THK-5117 PET imaging. Results: Seven patients had amyloid-β (Aβ, 4G8) plaques, two both Aβ and phosphorylated tau (P τ, AT8) and one only P τ in biopsy. As expected, increased brain biopsy Aβ was well associated with higher [ 11 C]PIB uptake in PET. However, S-[ 18 F]THK-5117 uptake did not show any statistically significant correlation with either brain biopsy P τ or CSF P-tau 181 or total tau. Conclusions: S-[ 18 F]THK-5117 lacked clear association with neuropathologically verified tau pathology in brain biopsy probably, at least partially, due to off-target binding. Further studies with larger samples of patients with different tau tracers are urgently needed. The detection of simultaneous Aβ and tau pathology in iNPH is important since that may indicate poorer and especially shorter response for CSF shunt surgery compared with no pathology.

29 September 2022 in Epilepsy Research
Verified
Journal Article
Closed access
JBJeffrey Buchhalter
Jeffrey Buchhalter
CNCaroline Neuray
Caroline Neuray
JCJocelyn Y. Cheng
Jocelyn Y. Cheng
ODO’nEill D’cRuz
O’nEill D’cRuz
ADAlexandre N. Datta
Alexandre N. Datta
PAPeter Van der Ark
Peter Van der Ark